Psoriasis

We are proud to be involved in the below studies here at St George Dermatology. While these studies are no longer recruiting new patients, we do have some exciting up and coming studies. Please contact us on 9587 4277 to discuss.

 

AbbVie–a 52 week trial of drug Adalimumab for treatment against plaque psoriasis and nail psoriasis. This drug is a TNF-alpha antagonist, and is given as an injection under the skin.

 

Lilly–a 5 year trial of drug ixekizumab in treatment against psoriasis. This drug is a monoclonal antibody against interleukin-17 and is given as an injection under the skin. This medication has been approved in Australia, and is now available on the PBS.

 

Novartis– a 2 year extension study with drug secukinumab in treatment against psoriasis. This drug is a monoclonal antibody against interleukin-17 and is given as an injection under the skin. This medication has been approved in Australia and is now available on the PBS.

 

Merck– a 64 week study (with additional 4 year extension study) with drug tildrakizumab in treatment against psoriasis. This drug is a monoclonal antibody against interleukin-23 and is given as an injection under the skin.

 

Coherus– a 48 week trial for patients who responded well to the base trial with a drug currently called CHS-0214 in treatment against psoriasis. This drug is a TNF-alpha inhibitor and is given as an injection under the skin.

 

Celgene– a one year trial, followed with optional four year extension, with drug Apremilast in treatment against psoriasis. This drug inhibits phosphodiesterase 4, which reduces production of pro-inflammatory messengers such as TNF-alpha and interleukin‑17 and ‑23. It is given as an injection under the skin.